ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors // Chi-Med
AIM: £45.10 (+0.35) | Nasdaq: $28.58 (-1.13)
News Archive
Previous Article   |   Next Article
Presentations | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors

1 Item
View Poster (JPG)